Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of nicotinamide mononucleotide and/or nicotinamide mononucleotide salt

A single nucleotide salt and single nucleotide technology, applied in the application field of nicotinamide mononucleotide and/or nicotinamide mononucleotide salt, can solve adverse reactions, easy recurrence, allergies requiring repeated medication, etc. problems, to achieve the effects of fewer adverse reactions, reduced sIgE synthesis, and reduced allergic recurrence rate

Inactive Publication Date: 2019-09-17
HOBOOMLIFE BIO TECH SHENZHEN CO LTD
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of this, the present invention provides an application of nicotinamide mononucleotide and / or nicotinamide mononucleotide salt, which is used to solve the problem of some adverse reactions of anti-allergic drugs, the need for repeated medication and allergic reactions in the prior art. Recurring Technical Defects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nicotinamide mononucleotide and/or nicotinamide mononucleotide salt

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] In this example, C3H / HeJ peanut-allergic mice were prepared by the following method: 6-week-old female C3H / HeJ mice were purchased from Shanghai Experimental Animal Center. The test animals are reared under specific non-pathogenic conditions in a room with an average temperature of 21° C. to 23° C. and a relative humidity of 40% to 70%, with a 12-hour light / dark cycle. The mice in the sensitization group were gavaged with peanut homogenate (single 80mg / each) every day, and on the 21st day after the implementation of the sensitization measures, the mice were given intraperitoneal injection (i.p) injection of 30mg CPE (peanut extract) / hour Rats, and young rats that had never been exposed to peanuts were used as negative controls. Then, by skin testing and anaphylaxis (by measuring vascular leak, monitoring clinical symptoms, rectal temperature, respiratory rate, and measuring serum mast cell protease-1 (mmcp-1) - a specific marker of mast cell degranulation) The assay co...

Embodiment 2

[0052] C3H / HeJ peanut-allergic mice in the test example of the present invention were prepared by the following method: 6-week-old female C3H / HeJ mice were purchased from Shanghai Experimental Animal Center. The test animals are reared under specific non-pathogenic conditions in a room with an average temperature of 21° C. to 23° C. and a relative humidity of 40% to 70%, with a 12-hour light / dark cycle. The mice in the sensitization group were gavaged with peanut homogenate (single 80mg / each) every day, and on the 21st day after the implementation of the sensitization measures, the mice were given intraperitoneal injection (i.p) injection of 30mg CPE (peanut extract) / hour Rats, and young rats that had never been exposed to peanuts served as negative controls. Then, by skin testing and anaphylaxis (by measuring vascular leak, monitoring clinical symptoms, rectal temperature, respiratory rate, and measuring serum mast cell protease-1 (mmcp-1) - a specific marker of mast cell deg...

Embodiment 3

[0072] 3.1 Experimental materials and experimental reagents:

[0073] The peripheral blood of healthy children of the same age and the peripheral blood (PBMC) of children with food allergy were obtained from Shenzhen Children's Hospital. IL10, TGF-β, IFN-γ and IgE antibodies (purchased from Sigma-aldrich), NMN (purchased).

[0074] 3.2 Experimental method

[0075] The peripheral blood (PBMC) of healthy children and food-allergic children were randomly collected, and the PBMCs were suspended in a medium (RPMI-1640; Mediatech) with 10% autologous plasma, and placed in a 37°C, 5% CO2 cell culture incubator. The training groups are as follows:

[0076] ①. Healthy group: PBMC (10^7 / ml) of healthy children were suspended in culture medium (0.2 mg / ml of physiological saline was added to the medium);

[0077] ②. Blank group: PBMC (10^7 / ml) from children with food allergy were suspended in culture medium (0.2 mg / ml of normal saline was added to the medium);

[0078] ③. Treatment gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of research and development of drugs and health-care products, and particularly relates to an application of nicotinamide mononucleotide and / or nicotinamide mononucleotide salt. The invention provides an application of the nicotinamide mononucleotide or the nicotinamide mononucleotide salt to anti-anaphylaxis drugs and / or anti-anaphylaxis health-care products. According to the technical scheme provided by the invention, after the nicotinamide mononucleotide or the nicotinamide mononucleotide salt (NMN) is used, Treg cells can be induced to secrete immunosuppression cytokine IL10, TGF-beta and the like, so that the immune reaction of TH2, blood basophilia and tissue mast cells can be restrained, sIgE synthesis is reduced, and finally the anaphylaxis symptoms can be alleviated; and further, through experimental determination, after the NMN is used, fewer adverse reactions exist, and the anaphylaxis recurrence rate is reduced. According to the application of the nicotinamide mononucleotide and / or the nicotinamide mononucleotide salt provided by the invention, the technical defects in the prior art that anti-anaphylaxis drugs have some adverse reactions, medication needs to be repeatedly performed, and the anaphylaxis recurs easily can be overcome.

Description

technical field [0001] The invention belongs to the field of research and development of medicines and health care products, and in particular relates to the application of nicotinamide mononucleotide and / or nicotinamide mononucleotide salt. Background technique [0002] Allergy is a series of hypersensitivity reactions caused by the human body's exposure to some allergens in the environment that have little impact on ordinary people, that is, the human body's excessive immunity to certain exogenous substances. Allergies include: immediate anaphylaxis (also known as IgE-mediated anaphylaxis), antibody-dependent and cytotoxic anaphylaxis, immune complex-mediated anaphylaxis, and delayed anaphylaxis. [0003] In the prior art, common anti-allergic drugs include: antihistamines, glucocorticoids, anti-leukotriene drugs, intranasal decongestants, etc. These drugs all have certain adverse reactions, and repeated medication is required to control symptoms. Allergies are prone to r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/706A61P37/08
CPCA61K31/706A61P37/08
Inventor 陈建生
Owner HOBOOMLIFE BIO TECH SHENZHEN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com